CompletedEarly Phase 1

Imaging the Neurochemistry of Drug Addiction With PET

United States25 participantsStarted 2017-11-29

Plain-language summary

The investigators' project has two overarching goals. 1) The investigators will use newly developed positron emission tomography (PET) technology to investigate the dopaminergic neurochemistry of drugs of abuse including marijuana, traditional cigarettes, and cocaine, and 2) The investigators will extend PET technology to an additional neurotransmitter system - namely, the opioid-ergic system, using the same drugs of abuse.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Men and women, aged 18-55 years
✓. Able to read and write English and give voluntary written informed consent
✓. Not treatment seeking or using treatment medications
✓. Have a Fagerström Test for Nicotine Dependence (FTND) rating of at least 3.
✓. Have been using at least 7 cigarettes per day for at least 1 year
✓. Carbon monoxide levels \> 10 ppm during intake evaluation
✓. Urine cotinine levels of \> 150 ng/mL during intake evaluation
✓. Are not current users of marijuana or other illicit drugs

What they're measuring

Change in Dopamine Levels at Baseline and After Drug of Dependence Administration as Confirmed by PET Images.

Timeframe: 90 minute PET scan acquisition. Drug of dependence will be given at -35 mins

Change in Beta Endorphin Levels at Baseline and After Drug of Dependence Administration as Confirmed by PET Images.

Timeframe: 120 minute PET scan acquisition. Drug of dependence will be given at -35 mins

Trial details

NCT IDNCT02817698

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-01-12

Results submitted2024-08-14

View on ClinicalTrials.gov More Smoking trials